1. Bristol-Myers Squibb Names José Baselga, MD, Ph.D. to Board of Directors

    Bristol-Myers Squibb Names José Baselga, MD, Ph.D. to Board of Directors

    NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. José is an internationally-recognized physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients, which he still continues today.
    2. With over 30 years of experience at the bench and in the clinic, José brings a voice of innovation and practical, patient-centric solutions to the Board.
    3. Bristol-Myers Squibb is a leader in harnessing the immune system to fight cancer, and their diverse pipeline of targeted therapies brings important hope for patients.
  3. Topics Mentioned